Fortrea Holdings Inc. (FTRE) - Stock Analysis

Last updated: Jul 26, 2026

Research Idea

Research content for general circulation. Not individualized advice.Ā Methodology & Disclosures

Fortrea displays strong operational momentum with raised revenue and backlog, cost savings, debt reductions, and a significant 50% rally in 3 weeks; however, margin compression, leverage, legal risk, and overextension temper conviction, requiring active risk management.

Loading chart data...

Idea window: 12/4/2025 – 12/11/2025Sector: Healthcare

AI Analyst Overview

Last Price
$20.70
Market Cap
$1.42B
1D Return
+7.81%
YTD Return
+20.00%

Loading chart data...

Valuation Metrics

P/E
-3.1
P/B
2.6
P/S
0.5
EV/EBITDA
-5.3
Div Yield
—

Price Behavior

7.0

Key Price Behavior Insights: • Higher lows • Former resistance flip • Stretched rally Support Level: $17.70-$17.00 Resistance Level: $19.50 FTRE has built a constructive last month uptrend, holding former resistance near $17.0-$17.3 as support and now pressing $19.5 resistance after a fast rally that could invite a short-term pullback.

bullish
watchlist

Sentiment & News

5.0

Key News Insights: • Legal probe • Earnings catalyst • Analyst support Fortrea faces a mixed outlook, with a July legal investigation tempering otherwise supportive analyst coverage and an upcoming July 29 Q2 earnings report serving as the key near-term catalyst.

FTRE
LegalProbe
AI

AI Summary

5.0
Neutral

FTRE now looks like a real recovery story because repeated 1.1x+ book-to-bill and strong Q1/guidance imply demand is holding up, but the stock has already rerated before margins, cash flow, and legal/leadership risks are resolved, so Q2 must confirm that bookings are converting into durable earnings improvement.

Recovery
Legal
Turnaround
AI summary updated 2 days ago

Description

Fortrea Holdings Inc. is a contract research organization that provides development services for biopharmaceuticals and medical devices globally. Its operations are organized into Clinical Services, covering clinical pharmacology and the spectrum of clinical development, and Enabling Services, which supplies patient access, trial technology, randomization and drug supply support. The company delivers these capabilities through full-service, functional service provider and hybrid models and also offers phase I–IV trial management and post-approval support; it was incorporated in 2023 and is based in Durham, North Carolina.

Idea History

DateCloseTickerCompanySummaryStatusP/L
Dec 4Dec 11FTREFortrea Holdings Inc.
Fortrea displays strong operational momentum with raised revenue and backlog, cost savings, debt reductions, and a significant 50% rally in 3 weeks; however, margin compression, leverage, legal risk, and overextension temper conviction, requiring active risk management.
Closed+7.2%
Research content for educational purposes only. Not investment advice. All decisions are your responsibility.